comparemela.com

Latest Breaking News On - தேசிய புற்றுநோய் மையம் சிங்கப்பூர் - Page 5 : comparemela.com

Breakthrough therapy for the most common type of leukaemia among children approved in Singapore

Breakthrough’ therapy for the most common type of leukaemia among children approved in Singapore Toggle share menu Advertisement Breakthrough’ therapy for the most common type of leukaemia among children approved in Singapore White blood cells are removed, genetically modified to attack cancer cells and put back into patients, in a treatment that was recently approved in Singapore. (Photo: Novartis) 24 Apr 2021 06:10AM) Share this content SINGAPORE: A type of cell therapy for  cancer has been approved for use in Singapore, providing another treatment option for patients with certain types of advanced blood cancers which are not in remission despite having gone through other forms of treatment. 

National Cancer Centre Singapore trial to evaluate benefits of TCM on cancer survivors quality of life

National Cancer Centre Singapore trial to evaluate benefits of TCM on cancer survivors quality of life Toggle share menu Advertisement Advertisement Singapore National Cancer Centre Singapore trial to evaluate benefits of TCM on cancer survivors quality of life Malt and wolfberry are some of the herbs used in the trial conducted at the National Cancer Centre Singapore. (Photo: Singapore Thong Chai Medical Institution) 22 Apr 2021 04:10PM) Share this content Bookmark SINGAPORE: Would patients who suffer from cancer-related fatigue benefit from traditional Chinese medicine (TCM)? That is the question the National Cancer Centre Singapore is trying to answer through a first-time trial involving TCM to treat the side effects of cancer. 

NCCS starts clinical trial to examine the use of TCM in countering cancer-related symptoms

NCCS starts clinical trial to examine the use of TCM in countering cancer-related symptoms The National Cancer Centre Singapore (NCCS) has started a clinical trial to examine the use of Traditional Chinese Medicine (TCM) in countering cancer-related symptoms or side effects of cancer treatment to improve cancer survivors quality of life. With advances in cancer diagnosis and treatment, cancer survivorship has improved significantly, but cancer survivors often experience a range of cancer-related and post-treatment side effects such as cancer-related fatigue. Cancer-related fatigue (CRF) refers to a distressing and persistent sense of physical, emotional and/or cognitive tiredness which is a side-effect of cancer or anti-cancer treatments. CRF is frequently experienced by cancer survivors and can interfere with their daily functioning. The HEalth-Related quality of life-intervention in survivors of Breast and other cancers experiencing CRF using TraditionAL Chinese Medicine, or the

Cancer surveillance co C2i Genomics raises $100m

Cancer surveillance co C2i Genomics raises $100m The company s cancer diagnostics service uses AI pattern recognition and whole-genome analysis to provide rapid and accurate detection of residual disease. Cancer surveillance company C2i Genomics has announced the completion of a $100 million financing round led by Casdin Capital with participation from NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital and others. The funding will accelerate clinical development and commercialization of the company’s C2-Intelligence Platform, a cancer diagnostics service that uses AI pattern recognition and whole-genome analysis to provide rapid and accurate detection of residual disease that is up to 100 times more sensitive than competing technologies.

C2i Genomics lands $100M to scale up software that detects tiny traces of cancer in a single blood draw

C2i Genomics lands $100M to scale up software that detects tiny traces of cancer in a single blood draw
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.